home / stock / inmb / inmb news


INMB News and Press, INmune Bio Inc. From 11/14/22

Stock Information

Company Name: INmune Bio Inc.
Stock Symbol: INMB
Market: NASDAQ
Website: inmunebio.com

Menu

INMB INMB Quote INMB Short INMB News INMB Articles INMB Message Board
Get INMB Alerts

News, Short Squeeze, Breakout and More Instantly...

INMB - INmune receives green signal from Canada to begin trial of XPro1595 in mild Alzheimer's Disease

INmune Bio ( NASDAQ: INMB ) said on Monday that Health Canada had issued a no objection letter to begin  trial of XPro1595 to treat mild Alzheimer’s Disease in Canada. "We are pleased that Canada is now part of this international Phase II trial,&#...

INMB - INmune Bio, Inc. Receives Health Canada "No Objection Letter" to Commence Clinical Trial of XPro1595 in Mild Alzheimer's Disease

BOCA RATON, FL., Nov. 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces...

INMB - INmune Bio, Inc. (INMB) Q3 2022 Earnings Call Transcript

INmune Bio, Inc. (INMB) Q3 2022 Results Conference Call November 02, 2022 04:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer Dr. CJ Barnum - Head of Neuroscience Dr. Mark Lowdell - Chief Scientific Offi...

INMB - INmune Bio GAAP EPS of -$0.43

INmune Bio press release ( NASDAQ: INMB ): Q3 GAAP EPS of -$0.43. As of September 30, 2022, the Company had cash and cash equivalents of approximately $57.4 million. For further details see: INmune Bio GAAP EPS of -$0.43

INMB - INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update

BOCA RATON, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported its fin...

INMB - INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2

Management to host conference call and webcast at 4:30 pm E T on that day Boca Raton, Florida, Oct. 26, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments tha...

INMB - INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune

Dr. Mark Lowdell, CSO, Presented Latest Data in First Plenary Session at The Innate Killer Summit Europe, London Today BOCA RATON, Fla, Oct. 19, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology compan...

INMB - An Overview Of Today's Alzheimer's Disease Development Field

Summary Alzheimer's Disease is one of the largest unmet medical needs. Today, there are 139 drugs in clinical trials for Alzheimer's. In this piece, we dive into 8 of the most impactful and promising trials. Introduction Alzheimer's disease is the largest unmet...

INMB - SA Interview: Biotech Investing With E. Roudasev

Summary E. Roudasev is a senior business manager for a major financial institution. Her areas of interest are biotech, environmental tech and credit risks. The opportunities in under the radar biotechs, typical sources of mispricings, and how to manage risk are topics discussed. ...

INMB - INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference

Boca Raton, FL, Sept. 07, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical- stage immunology company focused on developing treatments that harness the patient’s immune system to fight disease, announced today that RJ Tesi, M.D., Chief Executive Officer will present ...

Previous 10 Next 10